Microcap Ledger Jupiter Neurosciences, Inc. $JUNS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Jupiter, FL
- Fiscal year end
- December 31
- Shares outstanding
- 770,081 [10-Q 2026-08-14]
What the company doesAI summary of filing
Jupiter Neurosciences is a clinical-stage pharmaceutical company developing JOTROL™, an enhanced oral resveratrol formulation designed to treat neuroinflammatory conditions. The company is currently conducting a Phase IIa clinical trial in Parkinson's Disease and plans additional trials in mild cognitive impairment/early Alzheimer's disease and rare diseases including mucopolysaccharidosis type 1 and MELAS syndrome. In March 2025, the company launched Nugevia, a consumer-oriented nutritional supplement product line available through direct-to-consumer channels, with sales beginning in the fourth quarter of 2025. The company has not generated meaningful revenue from product sales to date and expects to continue incurring significant net losses. [10-K 2026-04-01]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $42.9K | −$4.34M | −$3.73M | $1.52M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $21.8K | −$8.64M | −$5.41M | $3.79M | [10-K 2026-04-01] |
| FY ended Dec 2024 | $0.00 | −$2.44M | −$3.91M | $3.77M | [10-K 2026-04-01] |
- Quarterly cash burn
- −$1.86M
- Cash runway Estimate
- ~2.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-12-23 | 33,103,860 | [10-Q 2024-12-23] |
| 2025-03-28 | 33,103,860 | [10-K 2025-03-28] |
| 2025-05-14 | 33,103,860 | [10-Q 2025-05-15] |
| 2025-08-18 | 34,833,083 | [10-Q 2025-08-19] |
| 2025-11-14 | 34,426,355 | [10-Q 2025-11-14] |
| 2026-03-31 | 36,281,252 | [10-K 2026-04-01] |
| 2026-05-14 | 36,281,252 | [10-Q 2026-05-14] |
| 2026-08-14 | 770,081 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-09-25; no effectiveness notice found in EDGAR [S-3 2026-09-25]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-28. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-28] |
| 2026-02-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-27] |
| 2025-03-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-25] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-03-02 | Hayward Marshall A. | exercise | 225,000 | — | [4 2026-07-13] |
| 2025-06-02 | Kampf Julie B. | exercise | 82,875 | — | [4 2026-07-13] |
| 2025-06-02 | Rosen Alexander Gustaf Erik | exercise | 164,553 | — | [4 2026-07-13] |
| 2025-06-02 | Rosen Alexander Gustaf Erik | exercise | 96,608 | — | [4 2026-07-13] |
| 2025-06-02 | Hayward Marshall A. | exercise | 389,793 | — | [4 2026-07-13] |
| 2025-06-02 | Hayward Marshall A. | exercise | 399,402 | — | [4 2026-07-13] |
| 2025-06-02 | Hemmerly Nicholas H. | exercise | 95,550 | — | [4 2026-07-13] |
| 2025-06-02 | Weis Holger | exercise | 85,800 | — | [4 2026-07-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-25 | S-3 | Registration statement |
| 2026-09-22 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-03 | 8-K | Charter, bylaws or fiscal year change |
| 2026-08-28 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-28 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-28 | 8-K | Listing notice or transfer; Other events |
| 2026-08-27 | 8-K | Material agreement entered; Director or officer change; Other events |
| 2026-08-24 | 8-K | Other events |
| 2026-08-24 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-08-24 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Other events |
Alerts for $JUNS
Email me when Jupiter Neurosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.